Bolt Biotherapeutics Stock Soars 49% in One Day: Inside the $120 Million Prana Reverse Merger

Bolt Biotherapeutics stock closed up about 49% on Friday, October 23, 2026, after the company announced a sign-and-close reverse merger to acquire Prana Therapies alongside a $120 million private placement.

Bolt Biotherapeutics (NASDAQ: BOLT) was one of the biggest gainers in the entire U.S. market on Friday. The stock traded as high as $7.78 during the session and closed around $6.25, up roughly 49% from Thursday's close of $4.19, on volume of more than 12.6 million shares — hundreds of times its recent average daily volume of roughly 32,000 shares. The catalyst was not a clinical readout. It was a deal, announced before the market opened, that effectively turns Bolt into a different company.

What happened

Before the open on October 23, Bolt announced it had acquired Prana Therapies through a sign-and-close, stock-for-stock reverse merger. In a reverse merger of this kind, the private company's owners end up controlling the combined, publicly listed business. That is exactly what the ownership terms show here.

Under the deal terms reported by TipRanks, existing Bolt shareholders will own just 6.9% of the combined company on a fully diluted basis. Prana Therapies equity holders will own 51.7%, and investors in a concurrent private placement will own the remaining 41.4%.

Alongside the merger, Bolt announced a $120 million private placement of Series D non-voting convertible preferred stock, with up to $60 million more available if related warrants are exercised. The placement is expected to close on October 26, 2026, and the company said it plans for the preferred stock to convert immediately, with the warrants exercised afterward.

Why it's blowing up

Three things explain the size of the move. First, the money: $120 million of new capital, with a possible $60 million more, is a very large financing relative to Bolt's size before the deal — the company had reported about $18.1 million in cash and securities at June 30, and its market value before Friday was only around $8 million, according to OpenBio News analysis.

Second, the pipeline changes completely. After the merger, Bolt said it intends to focus on Prana's pipeline, led by PRA-216, a bispecific antibody already in Phase 2 development for asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. A fourth Phase 2 study, in eosinophilic esophagitis, is also planned.

Third, the float was tiny. With only about 1.9 million shares outstanding before the deal and average daily volume near 32,000 shares, Friday's turnover of more than 12 million shares meant the stock changed hands many times over in a single session — the kind of volume spike that regularly produces outsized percentage moves in small biotech names.

Key facts

• Deal: Bolt Biotherapeutics acquired Prana Therapies in a sign-and-close, stock-for-stock reverse merger announced before the open on October 23, 2026.
• Financing: A concurrent $120 million private placement, expected to close October 26, with up to $60 million more available on warrant exercise.
• Ownership after the deal: Existing Bolt holders 6.9%, Prana holders 51.7%, placement investors 41.4% (fully diluted, per TipRanks).
• Lead asset: PRA-216, in Phase 2 for asthma, COPD and atopic dermatitis, with a planned Phase 2 study in eosinophilic esophagitis; data from the four studies is expected between the second and fourth quarters of 2027.
• Runway: The upfront proceeds are expected to fund operations into 2028, according to coverage of the announcement.
• Leadership: Prana founder and former CEO Sheila Gujrathi will join Bolt as chief strategy officer and as a member of its board.
• Price action: BOLT closed around $6.25 on Friday, up about 49%, after an intraday high of $7.78, on volume above 12.6 million shares.

Sources: TipRanks, OpenBio News, InvestorIdeas, StockSetups market movers

What happens to Bolt's old pipeline?

Bolt's own programs — led by BDC-4182, an experimental cancer immunotherapy in early-stage testing, plus several programs the company had already placed on hold during a 2025 restructuring — are no longer the stated focus. The combined company's stated priority is Prana's INSPIRE platform and PRA-216. Friday's rally, analysts noted, was therefore not a re-rating of Bolt's original science; it was the market pricing a new company — a Phase 2 immunology asset, $120 million of fresh capital and a Nasdaq listing — into Bolt's shares.

What's next

The immediate milestone is the expected October 26 closing of the $120 million placement. After that, attention shifts to execution: starting the planned eosinophilic esophagitis study, advancing the three ongoing Phase 2 trials of PRA-216, and the first data readouts, which are not expected until 2027. Investors should also note the flip side of Friday's structure: existing Bolt shareholders were diluted to a 6.9% stake, and small, thinly traded biotech stocks that move this fast in one session have a long history of sharp moves in both directions. This post reports what happened and why markets reacted; it is not financial advice, and it is not a recommendation to buy, sell or hold any security.

FAQ

Why did Bolt Biotherapeutics stock surge on October 23, 2026?

Bolt announced before the open that it had acquired Prana Therapies in a stock-for-stock reverse merger, alongside a $120 million private placement expected to close on October 26, with up to $60 million more available on warrant exercise.

What is PRA-216?

PRA-216 is Prana Therapies' lead drug candidate, a bispecific antibody in Phase 2 testing for asthma, COPD and atopic dermatitis, with a fourth Phase 2 study planned in eosinophilic esophagitis and data expected in 2027.

How much of the combined company do existing Bolt shareholders own?

Existing Bolt shareholders own 6.9% of the combined company on a fully diluted basis, while Prana holders own 51.7% and the new placement investors own 41.4%, according to the reported deal terms.

How far did BOLT stock move?

BOLT closed around $6.25 on Friday, up about 49% on the day, after trading as high as $7.78, on volume of more than 12.6 million shares — hundreds of times its recent average daily volume.